Brandywine Oak Private Wealth LLC Makes New $213,000 Investment in Cencora, Inc. $COR

Brandywine Oak Private Wealth LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 712 shares of the company’s stock, valued at approximately $213,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. boosted its stake in Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cencora by 4,459.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after buying an additional 787,858 shares in the last quarter. Nuveen LLC bought a new stake in Cencora during the 1st quarter worth about $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec increased its position in Cencora by 144.4% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after acquiring an additional 439,008 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on COR. Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Wells Fargo & Company lifted their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research note on Wednesday. Evercore ISI set a $340.00 price target on Cencora in a report on Wednesday. Finally, Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $320.00.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock worth $16,292,923 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Cencora Price Performance

Shares of COR opened at $318.01 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The stock has a market cap of $61.66 billion, a P/E ratio of 32.72, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The stock’s 50-day moving average price is $296.99 and its two-hundred day moving average price is $291.60. Cencora, Inc. has a 1 year low of $221.95 and a 1 year high of $319.68.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. Cencora’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the company posted $3.34 EPS. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 22.63%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.